Tetracyclines

Bacterial drug resistance has become a core challenge in the global anti-infection field. As an important branch of classic broad-spectrum antibiotics, tetracyclines block protein synthesis by specifically binding to the 30S subunit of bacterial ribosomes and inhibiting the ligation of aminoacyl-tRNA, and have long occupied a key position in the prevention and control of clinical infections. This class of drugs not only covers Gram-positive and Gram-negative bacteria, but is also effective against atypical pathogens such as Mycoplasma, Chlamydia and Rickettsia. In addition to the treatment of conventional respiratory, genitourinary, and skin and soft tissue infections, derivatives such as doxycycline and minocycline are also used for special indications such as acne, Helicobacter pylori eradication, and brucellosis. The applicable population covers adults and pediatric patients in special scenarios, making them indispensable basic drugs for both primary medical care and high-end infection diagnosis and treatment scenarios.

At present, the global market size of tetracycline API is stably maintained at more than 1.2 billion US dollars, with a compound annual growth rate of about 3.8%, showing obvious rigid demand characteristics. China is the world's largest producer and exporter of tetracycline API, with production capacity accounting for more than 85% of the global total. Leading manufacturers are concentrated in Hebei, Shandong and other regions, with outstanding cost advantages and technological maturity. With the gradual improvement of the allocation of anti-infection drugs in primary medical institutions and the release of large-scale demand for veterinary tetracycline products, the average annual growth rate of the domestic API market is slightly higher than the global level, about 4.5%. Moreover, after the implementation of centralized procurement, the volume expansion of generic drug preparations has further driven the demand for upstream API to concentrate on compliant production capacity, and the industry concentration continues to increase.

The original research of tetracycline drugs was first developed by Pfizer in the United States. The first marketed product oxytetracycline has the trade name "Terramycin", and the core compound patents fully expired in the 1970s. The original research of the subsequent derivative doxycycline is Pfizer, with the trade name "Vibramycin", and the original research of minocycline is Wyeth (now merged into Pfizer), with the trade name "Minocin". The core patents of both expired before 2000. At present, the commonly used dosage forms include tablets, capsules and injections, with conventional specifications of 50mg and 100mg. Relevant reference preparations have been included in the NMPA List of Reference Preparations for Chemical Drugs and the FDA Orange Book. At present, more than 30 domestic enterprises have obtained CDE registration numbers for tetracycline API, and there are more than 600 relevant preparation approvals, with a mature and stable supply system. (Data as of September 2024, please refer to the official CDE website for the latest information)

CATO provides a full range of API impurity reference standards for tetracyclines, covering relevant impurities of all mainstream varieties such as doxycycline, minocycline and oxytetracycline. Most products are in stock. For in-stock orders placed before 16:00, delivery can be made on the same day. The products also meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the full-process needs of enterprises in API R&D, quality research and registration declaration.